Psoriatic arthritis Trials in Freehold, United States
Conditions / Psoriatic arthritis / Freehold, United States
Clinical trials for Psoriatic arthritis investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05511519 | Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis | TERMINATED | PHASE2 |
| NCT01392326 | Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) | COMPLETED | PHASE3 |
| NCT03104400 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | COMPLETED | PHASE3 |
| NCT01892436 | Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT01989468 | 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT02376790 | Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT04109976 | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT04009499 | A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01752634 | Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT03896581 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | COMPLETED | PHASE3 |